Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Buy" by Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given an average recommendation of "Buy" by the six analysts that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $22.20.

LXEO has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $23.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, April 8th. Leerink Partners lowered their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a research report on Monday, March 24th. Royal Bank of Canada dropped their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 25th. Finally, Chardan Capital cut their price objective on shares of Lexeo Therapeutics from $25.00 to $22.00 and set a "buy" rating on the stock in a research report on Tuesday, April 8th.

Lexeo Therapeutics Trading Up 16.9 %

LXEO stock traded up $0.67 during midday trading on Friday, reaching $4.60. 193,745 shares of the company's stock traded hands, compared to its average volume of 645,944. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a fifty-two week low of $1.45 and a fifty-two week high of $19.50. The business has a 50-day moving average price of $2.97 and a two-hundred day moving average price of $5.49. The company has a market capitalization of $152.57 million, a P/E ratio of -1.45 and a beta of 1.52.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.09. Equities research analysts forecast that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in shares of Lexeo Therapeutics by 86.5% in the 3rd quarter. Geode Capital Management LLC now owns 553,247 shares of the company's stock worth $5,003,000 after purchasing an additional 256,635 shares during the last quarter. State Street Corp boosted its stake in shares of Lexeo Therapeutics by 29.4% during the 3rd quarter. State Street Corp now owns 253,946 shares of the company's stock worth $2,296,000 after acquiring an additional 57,674 shares in the last quarter. Barclays PLC grew its holdings in shares of Lexeo Therapeutics by 162.2% in the 3rd quarter. Barclays PLC now owns 50,210 shares of the company's stock worth $454,000 after acquiring an additional 31,057 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Lexeo Therapeutics by 48.3% during the fourth quarter. Wellington Management Group LLP now owns 76,981 shares of the company's stock worth $507,000 after purchasing an additional 25,089 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Lexeo Therapeutics by 19.6% in the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company's stock valued at $166,000 after purchasing an additional 4,127 shares during the period. Institutional investors own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.